Browse our complete database | AME

All filters

Slidesets

90-90-90 for all - Scale up of HIV Treatment for Adolescents | Victor Musiime, MBChB, MMED, PhD

Presented at:

INTEREST 2016

Slidesets

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Affirming the motion | Mauro Schechter, MD, PhD

Presented at:

INTEREST 2016

Slidesets

(Abstract) Ultra-deep pyrosequencing of paediatric HIV-1 drug resistance and coreceptor suggests possible suitability of protease inhibitors and maraviroc at younger ages in Cameroon | J. Fokam

Presented at:

INTEREST 2016

Slidesets

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Opposing the motion | Badara Samb, MD, PhD

Presented at:

INTEREST 2016

Slidesets

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Affirming the motion | Isaac Tita

Presented at:

INTEREST 2016

Slidesets

(Abstract) Prevalence of non-infectious co-morbidities among HIV-positive subjects stably treated with tenofovir, lamivudine and ritonavir-boosted lopinavir in Cameroon | D. Fokom Victoire

Presented at:

INTEREST 2016

Slidesets

(Abstract) Current profile of dermatological diseases and events during HIV in Dakar | N.M.Dia

Presented at:

INTEREST 2016

Slidesets

(Abstract) Quality of life among HIV/AIDS patients on anti retro-viral therapy at Letlhakane primary hospital (Botswana): a cross sectional study | L. Kumboneki

Presented at:

INTEREST 2016

Slidesets

(Abstract) Model-based pediatric dosing of ritonavir-boosted Darunavir: an alternative to WHO guidelines | P. Mohammed

Presented at:

INTEREST 2016

Slidesets

(Abstract) Maximizing EID opportunities using the DBS Mentor Approach in Rural HIV Clinics in South-Eastern Nigeria | P. Anyanwu

Presented at:

INTEREST 2016

Slidesets

(Abstract) Getting pregnant in antiretroviral clinical trials: women choice and safety needs. Experience from the ANRS12169-2LADY and ANRS12286- MOBIDIP trials | A. Serris

Presented at:

INTEREST 2016

Slidesets

(Abstract) Retention in care among HIV-infected pregnant mothers on lifelong antiretroviral therapy (art) in Uganda | S. Muhumuza

Presented at:

INTEREST 2016

Slidesets

(Abstract) Immunologic Criteria are Poor Predictors of Virologic Outcomes: Implications for HIV Monitoring in a Large Treatment Program in Nigeria | J. Okuma

Presented at:

INTEREST 2016

Slidesets

(Abstract) Factors associated with virologic failure in HIV infected individuals in Mansa district, Zambia | G. Mutaawe

Presented at:

INTEREST 2016

Slidesets

Sustaining progress on scale-up of voluntary medical male circumcision (VMMC), including role of devices and early infant male circumcision | Zebedee Mwandi, MD

Presented at:

INTEREST 2016

Slidesets

Dolutegravir in contributing the 90:90:90 ambition | Tuna Lukiana MD, PhD

Presented at:

INTEREST 2016

Slidesets

New evidence on oral and topical PrEP for women: rings, gels, injectables | Nyaradzo Mgodi, MBChB, MMed

Presented at:

INTEREST 2016

Slidesets

Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation | Speaker for the Opposition | François Venter, MD, FCP, PhD

Presented at:

INTEREST 2016

Slidesets

Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation | Community Advocate | Stephen Watiti, MD

Presented at:

INTEREST 2016

Slidesets

(Abstract) Predictors of HIV-testing in South African adolescents: schools-based testing, pregnancy and sexual experience | C. Carty

Presented at:

INTEREST 2016

Slidesets

Trial, post-trial, & demonstration project results for Pre-exposure Prophylaxis (PrEP) | Elizabeth Irungu, MBChB, MPH

Presented at:

INTEREST 2016

Slidesets

(Abstract) EDCTP as a model for Europe-Africa partnership on HIV/AIDS research and capacity development: Examples from Cameroon | L.J. Pandya

Presented at:

INTEREST 2016

Slidesets

(Abstract) Tenofovir-containing first-line ART favourably reduce inflammation markers compared to thymidine analogue nucleoside reverse-transcriptase inhibitors | S. Kroeze

Presented at:

INTEREST 2016

Slidesets

(Abstract) Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children | T.S.Boender

Presented at:

INTEREST 2016